Abstract
This review highlights the ways in which molecular and genetic profiling of malignant gliomas has led to intelligent clinical trial design. The review also highlights known resistance mechanisms to conventional therapies in malignant gliomas and potential strategies to overcome these mechanisms with the use of targeted therapy.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / genetics
-
Brain Neoplasms / metabolism*
-
Clinical Trials as Topic*
-
Gene Expression Profiling*
-
Glioblastoma / drug therapy
-
Glioblastoma / genetics
-
Glioblastoma / metabolism*
-
Humans
-
Research Design*
-
Signal Transduction / drug effects*